Due to the concerning rise in sexually transmitted infection (STIs) transmission across Europe, the European Centre for Disease Prevention and Control (ECDC) is urging everyone to keep informed and practice safer sex as they leave for holidays, festivals, and travel this summer season.
On this episode we are joined by Otilia Mårdh, Medical Epidemiologist at ECDC, to discuss the latest reports on sexually transmitted infections in Europe.
In a series of reports released by ECDC, a concerning rise in sexually transmitted infections (STIs) across Europe has been revealed indicating troubling trends and significant public health implications.
Following a decline in notification rates in 2016, the number of gonorrhoea cases has gone up by 17% across the reporting EU/EEA countries with more than 89 000 confirmed diagnoses in 2017 – more than 240 cases a day.
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Gonorrhoea is the second most commonly notified sexually transmitted infection across the EU/EEA countries with almost 500 000 reported cases between 2007 and 2016. The infection is treatable but Neisseria gonorrhoeae keep showing high levels of azithromycin resistance according to latest results of the European Gonococcal Antimicrobial Surveillance Programme.
The Carnival season will last from 1 to 9 March 2019. In Rio de Janeiro, Brazil, 1 million participants are expected, including many travellers from Europe
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens?